LAVA Therapeutics N.V. announced the Company will present updated interim data from the dose escalation phase of the ongoing Phase 1/2a clinical trial of LAVA-051 in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma at the 2022 American Society of Clinical Oncology Annual Meeting taking place in Chicago and virtually June 3-7, 2022.
UTRECHT, The Netherlands and PHILADELPHIA, April 27, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.(Nasdaq:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the Company will present updated interim data from the dose escalation phase of the ongoing Phase 1/2a clinical trial of LAVA-051 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022.
The details of the poster presentation session are as follows:
Abstract #: 2577
Abstract Title: Phase I dose escalation of LAVA-051, a novel bispecific gamma delta T-cell engager (Gammabody™), in relapsed/refractory hematological malignancies
Session Title: Developmental Therapeutics — Immunotherapy
Session Date: Sunday, June 5, 2022
Session Time: 8–11 a.m. CDT/9 a.m.–12 p.m. EDT
Presenter: Benjamin Winograd, M.D., Ph.D., chief medical officer, LAVA Therapeutics
About LAVA Therapeutics
LAVA Therapeutics N.V. is an immuno-oncology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematological malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor associated antigens. LAVA-051, the Company’s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study (NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling. For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitterand YouTube.
LAVA’sCautionaryNoteonForward-LookingStatements
This press release contains forward-looking statements, including in respect to the company’s anticipatedgrowth and clinical developments plans, including the timing of clinical trials. Words such as “anticipate,”“believe,” “could,” “will,” “may,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential” and similarexpressions(aswellasotherwordsorexpressionsreferencingfutureevents,conditionsorcircumstances) are intended to identify forward-looking statements. These forward-looking statements are based onLAVA’s expectations and assumptions as of the date of this press release and are subject to various risksanduncertaintiesthatmaycauseactualresultstodiffermateriallyfromtheseforward-lookingstatements. Forward-looking statements contained in this press release include, but are not limited to,statements about the preclinical data, clinical development and scope of clinical trials, and the potentialuse of our product candidates to treat various tumor targets. Many factors, risks and uncertainties maycause differences between current expectations and actual results including, among other things, thetimingandresultsofourresearchanddevelopmentprogramsandpreclinicalandclinicaltrials,ourabilityto obtain regulatory approval for and commercialize our product candidates, our ability to leverage ourinitial programs to develop additional product candidates using our Gammabody™ platform, and thefailureofLAVA’scollaboratorstosupportoradvancecollaborationsorourproductcandidates.Inaddition,the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend,including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing andsupply chain, or impairing employee productivity. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new informationbecomes available.
CONTACTS
Edward Smith
Chief Financial Officer
ir@lavatherapeutics.com
Argot Partners (IR/Media)
212-600-1902
lava@argotpartners.com
